JP6879905B2 - ＲＧＭａ断片ベース診断アッセイ - Google Patents

ＲＧＭａ断片ベース診断アッセイ Download PDF

Info

Publication number
JP6879905B2
JP6879905B2 JP2017513509A JP2017513509A JP6879905B2 JP 6879905 B2 JP6879905 B2 JP 6879905B2 JP 2017513509 A JP2017513509 A JP 2017513509A JP 2017513509 A JP2017513509 A JP 2017513509A JP 6879905 B2 JP6879905 B2 JP 6879905B2
Authority
JP
Japan
Prior art keywords
rgma
kda
fragment
rgma fragment
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017513509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526930A5 (enExample
JP2017526930A (ja
Inventor
バルクホルン，シュテファン
ミュラー，ベルンハルト・クラウス
シュミット，マルティン
シュトリービンガー・アンドレーアス
Original Assignee
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー filed Critical アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー
Publication of JP2017526930A publication Critical patent/JP2017526930A/ja
Publication of JP2017526930A5 publication Critical patent/JP2017526930A5/ja
Application granted granted Critical
Publication of JP6879905B2 publication Critical patent/JP6879905B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
JP2017513509A 2014-09-10 2015-09-09 ＲＧＭａ断片ベース診断アッセイ Expired - Fee Related JP6879905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10
US62/048,745 2014-09-10
PCT/EP2015/070603 WO2016038084A1 (en) 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay

Publications (3)

Publication Number Publication Date
JP2017526930A JP2017526930A (ja) 2017-09-14
JP2017526930A5 JP2017526930A5 (enExample) 2018-10-18
JP6879905B2 true JP6879905B2 (ja) 2021-06-02

Family

ID=54064367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513509A Expired - Fee Related JP6879905B2 (ja) 2014-09-10 2015-09-09 ＲＧＭａ断片ベース診断アッセイ

Country Status (10)

Country Link
US (3) US20160069907A1 (enExample)
EP (1) EP3191847A1 (enExample)
JP (1) JP6879905B2 (enExample)
CN (2) CN107076757A (enExample)
AU (2) AU2015314240A1 (enExample)
BR (1) BR112017004883A2 (enExample)
CA (1) CA2956814A1 (enExample)
MX (2) MX385216B (enExample)
TW (2) TW202119030A (enExample)
WO (1) WO2016038084A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
CN116942831A (zh) 2018-07-19 2023-10-27 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
CN118767130A (zh) * 2020-01-15 2024-10-15 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
US12306192B2 (en) 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
EP4374300A4 (en) * 2021-07-23 2025-06-11 Cedars-Sinai Medical Center Methods and systems for the early detection of ocular and/or neurological conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
KR102284780B1 (ko) * 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
EP3252072A3 (en) * 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas

Also Published As

Publication number Publication date
CN107076757A (zh) 2017-08-18
BR112017004883A2 (pt) 2017-12-05
AU2022200160A1 (en) 2022-02-10
US20160069907A1 (en) 2016-03-10
EP3191847A1 (en) 2017-07-19
US20220018855A1 (en) 2022-01-20
WO2016038084A1 (en) 2016-03-17
TW202119030A (zh) 2021-05-16
CA2956814A1 (en) 2016-03-17
US20200241012A1 (en) 2020-07-30
AU2015314240A1 (en) 2017-02-09
CN113267630A (zh) 2021-08-17
MX2021009528A (es) 2021-09-08
JP2017526930A (ja) 2017-09-14
MX385216B (es) 2025-03-14
MX2017003063A (es) 2017-06-14
TW201617612A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
JP6879905B2 (ja) ＲＧＭａ断片ベース診断アッセイ
US8048635B2 (en) Measurement of soluble Tweak levels for evaluation of lupus patients
US10274503B2 (en) Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
Wang et al. Serum matrix metalloproteinase-2: A potential biomarker for diagnosis of epilepsy
BRPI0807601B1 (pt) método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos
US7709215B2 (en) Method for diagnosing and treating acute joint injury
Andreopoulos et al. Chronic lithium treatment of B lymphoblasts from bipolar disorder patients reduces transient receptor potential channel 3 levels
US8609432B2 (en) Method and kit for detection of autoimmune chronic urticaria
US9139879B2 (en) TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
JP7713445B2 (ja) 薬物誘発細胞毒性及び鬱病のバイオマーカー
US20230273220A1 (en) Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection
US20200124612A1 (en) Detection of predictors of preeclampsia
US11041863B2 (en) Frizzled-4 mutation indicator of retinopathy and intrauterine growth restriction
US20210382049A1 (en) Assessing responsiveness of rheumatoid arthritis patients to biological treatment
US20060263761A1 (en) Methods and compositions for beryllium-induced Disease
JPWO2009020058A1 (ja) 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー
US20250180583A1 (en) Diagnosis markers of parkinson's disease
EP3570028A1 (en) Assessing responsiveness of rheumatoid arthritis patients to biological treatment
US20090162854A1 (en) Methods and kits for diagnosis of schizophrenia
EP1506411A1 (en) Method for identifying type-i interferon responsive ms patients by determining trail expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210430

R150 Certificate of patent or registration of utility model

Ref document number: 6879905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees